Literature DB >> 2902265

Effect of dry-heating of coagulation factor concentrates at 80 degrees C for 72 hours on transmission of non-A, non-B hepatitis. Study Group of the UK Haemophilia Centre Directors on Surveillance of Virus Transmission by Concentrates.

.   

Abstract

32 patients with coagulation factor deficiencies and likely to be susceptible to non-A, non-B hepatitis (NANBH) virus infection were treated with a total of 20 batches of a factor VIII concentrate and 10 batches of a factor IX concentrate, both heated at 80 degrees C for 72 h in the freeze-dried state. Serial measurements of serum aminotransferase levels for 4 months revealed no patterns of rises attributable to NANBH. Severe dry heating appears to have reduced the risk of NANBH transmission from about 90% in untreated concentrates to a statistically determined rate of 0-9%. No evidence was found in recipients of infection with hepatitis B or human immunodeficiency virus.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2902265

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  6 in total

Review 1.  State of care for hemophilia in pediatric patients.

Authors:  Elena Santagostino; Alessandro Gringeri; Pier M Mannucci
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

2.  Effects of Gαi2 and Gαz protein knockdown on alpha2A-adrenergic and cannabinoid CB1 receptor regulation of MEK-ERK and FADD pathways in mouse cerebral cortex.

Authors:  Alfredo Ramos-Miguel; Pilar Sánchez-Blázquez; Jesús A García-Sevilla
Journal:  Pharmacol Rep       Date:  2021-02-28       Impact factor: 3.024

3.  Clinical assessment of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A.

Authors:  A Dmoszynska; K Kuliczkowski; A Hellmann; J Trelinski; J Kloczko; T Baglin; C Hay; D O'Shaughnessy; K Zawilska; M Makris; R Shaikh-Zaidi; E Gascoigne; C Dash
Journal:  Haemophilia       Date:  2011-03-04       Impact factor: 4.287

Review 4.  Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.

Authors:  Robert Klamroth; Albrecht Gröner; Toby L Simon
Journal:  Transfusion       Date:  2013-09-30       Impact factor: 3.157

5.  Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins.

Authors:  Christoph Kempf; Martin Stucki; Nicola Boschetti
Journal:  Biologicals       Date:  2006-04-03       Impact factor: 1.856

Review 6.  Intravenous immunoglobulins: evolution of commercial IVIG preparations.

Authors:  John A Hooper
Journal:  Immunol Allergy Clin North Am       Date:  2008-11       Impact factor: 3.479

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.